FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 18,900 shares of the business’s stock in a transaction dated Thursday, January 18th. The stock was sold at an average price of $47.64, for a total transaction of $900,396.00. Following the completion of the sale, the chief executive officer now owns 2,981,447 shares in the company, valued at $142,036,135.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
FibroGen Inc (FGEN) traded down $0.30 during trading on Friday, reaching $50.70. 852,809 shares of the company’s stock traded hands, compared to its average volume of 639,327. The stock has a market cap of $4,167.39, a PE ratio of -24.85 and a beta of 1.74. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83. FibroGen Inc has a 12 month low of $22.75 and a 12 month high of $63.00.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.13). FibroGen had a negative return on equity of 47.36% and a negative net margin of 120.00%. research analysts predict that FibroGen Inc will post -1.75 earnings per share for the current year.
FGEN has been the subject of a number of recent analyst reports. Mizuho reaffirmed a “hold” rating and set a $61.00 price target on shares of FibroGen in a research note on Thursday, November 9th. ValuEngine cut shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Finally, BidaskClub cut shares of FibroGen from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Four analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. FibroGen has a consensus rating of “Buy” and a consensus target price of $65.67.
Institutional investors and hedge funds have recently made changes to their positions in the company. Quantbot Technologies LP purchased a new stake in shares of FibroGen in the 2nd quarter worth approximately $128,000. Bank of Montreal Can lifted its position in shares of FibroGen by 2,097.2% in the 4th quarter. Bank of Montreal Can now owns 3,186 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 3,041 shares during the period. Fortaleza Asset Management Inc. lifted its position in shares of FibroGen by 95.0% in the 4th quarter. Fortaleza Asset Management Inc. now owns 3,490 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 1,700 shares during the period. Ameritas Investment Partners Inc. lifted its position in shares of FibroGen by 15.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,218 shares of the biopharmaceutical company’s stock worth $169,000 after purchasing an additional 696 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of FibroGen by 41.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,883 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 1,147 shares in the last quarter. 57.11% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Thomas B. Neff Sells 18,900 Shares of FibroGen Inc (NASDAQ:FGEN) Stock” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://ledgergazette.com/2018/02/12/fibrogen-inc-fgen-ceo-thomas-b-neff-sells-18900-shares.html.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.